גאלבוס 50 מ"ג

Pays: Israël

Langue: hébreu

Source: Ministry of Health

Ingrédients actifs:

VILDAGLIPTIN 50 MG

Disponible depuis:

NOVARTIS PHARMA SERVICES AG

Code ATC:

A10BH02

forme pharmaceutique:

TABLETS

Mode d'administration:

PER OS

Fabriqué par:

NOVARTIS PHARMA STEIN AG, SWITZERLAND

Groupe thérapeutique:

VILDAGLIPTIN

indications thérapeutiques:

Galvus is indicated as an adjunct to diet and exercise in patients with type 2 diabetes mellitus• As monotherapy, if diet and exercise are not sufficient, or• In combination with metformin, or a sulfonylurea if treatment with these oral antidiabetics does not offer sufficient control of blood glucose.As triple oral therapy in combination with• a sulphonylurea and metformin when diet and exercise plus dual therapy with these agents do not provide adequate glycaemic control. Galvus is also indicated for use in combination with insulin (with or without metformin) when diet and exercise plus a stable dose of insulin do not provide adequate glycaemic control.

Date de l'autorisation:

2008-12-01